Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK considers gauging latent vCJD infection with tests on all postmortems

This article was originally published in Clinica

Executive Summary

The UK government is considering extending postmortem examinations with tests for variant Creutzfeldt-Jakob disease (vCJD), in order to better gauge the extent of latent infection across the entire population. Concerned that 166 UK deaths to date may not reflect the true prevalence, with the significant risk that this poses to transmission through surgery and blood transfusion, the Department of Health (DoH) wants postmortems to include tests on tissues that are known to accumulate the prion protein responsible for vCJD, such as the spleen and the brain. Some 115,000 postmortems are ordered by coroners every year in England alone. The Coroners' Society for England and Wales has criticised the initiative as "inappropriate", but the Health Protection Agency and DoH are reportedly keen to develop the plans and are assessing the practical and legal implications.

You may also be interested in...



Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

Topics

UsernamePublicRestriction

Register

MT046217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel